Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes
- PMID: 19324411
- PMCID: PMC2749891
- DOI: 10.1016/j.leukres.2009.02.005
Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes
Abstract
Comorbid conditions have rarely been systematically studied among patients with myelodysplastic syndromes (MDS). We conducted a large population-based study to assess the role of comorbidity in the survival of newly diagnosed MDS patients. This study included 1708 MDS patients (age > or =66 years) diagnosed in the US during 2001-2002, with follow-up through the end of 2004. Hazard ratios (HRs) were estimated using multivariate Cox proportional hazard models. The median survival time was approximately 18 months. Fifty one percent of MDS patients had comorbid conditions. Patients with comorbid conditions had significantly greater risk of death than those without comorbidities. The HR was 1.19 (95% confidence interval (CI): 1.05-1.36) and 1.77 (95% CI: 1.50-2.08) for those with a Charlson index of 1-2 and > or = 3, respectively. The risk of death increases with Charlson index. MDS patients who have congestive heart failure or chronic obstructive pulmonary disease had significantly shorter survival than patients without those conditions, whereas diabetes did not appear to have an impact on survival. This study confirms comorbidity as a significant and independent determinant of MDS survival, and the findings underscore the importance to take comorbid conditions into account when assessing the prognosis of MDS.
Figures
Similar articles
-
Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.Blood Adv. 2021 Mar 9;5(5):1344-1351. doi: 10.1182/bloodadvances.2020003381. Blood Adv. 2021. PMID: 33656535 Free PMC article.
-
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6. Haematologica. 2011. PMID: 21134982 Free PMC article.
-
The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.Med Oncol. 2018 Feb 8;35(3):33. doi: 10.1007/s12032-018-1094-7. Med Oncol. 2018. PMID: 29417235
-
Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.Autoimmun Rev. 2019 Jan;18(1):36-42. doi: 10.1016/j.autrev.2018.07.009. Epub 2018 Nov 5. Autoimmun Rev. 2019. PMID: 30408583 Review.
-
Classification and prognostic evaluation of myelodysplastic syndromes.Semin Oncol. 2011 Oct;38(5):627-34. doi: 10.1053/j.seminoncol.2011.04.007. Semin Oncol. 2011. PMID: 21943669 Review.
Cited by
-
The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus.J Cancer Res Clin Oncol. 2024 Feb 2;150(2):71. doi: 10.1007/s00432-023-05591-4. J Cancer Res Clin Oncol. 2024. PMID: 38305890 Free PMC article.
-
Somatic mutations show no clear association with red blood cell or human leukocyte antigen alloimmunization in de novo or therapy-related myelodysplastic syndrome.Transfusion. 2022 Dec;62(12):2470-2479. doi: 10.1111/trf.17155. Epub 2022 Oct 24. Transfusion. 2022. PMID: 36278434 Free PMC article.
-
Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes.Front Oncol. 2022 Apr 1;12:846044. doi: 10.3389/fonc.2022.846044. eCollection 2022. Front Oncol. 2022. PMID: 35433406 Free PMC article.
-
Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.Blood Adv. 2021 Mar 9;5(5):1344-1351. doi: 10.1182/bloodadvances.2020003381. Blood Adv. 2021. PMID: 33656535 Free PMC article.
-
Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq.Sultan Qaboos Univ Med J. 2019 Aug;19(3):e236-e241. doi: 10.18295/squmj.2019.19.03.010. Epub 2019 Nov 5. Sultan Qaboos Univ Med J. 2019. PMID: 31728222 Free PMC article.
References
-
- Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–1542. - PubMed
-
- Bennett J, Cheson B, editors. Basic and Clinical Oncology. Vol. 27. New York: Marcel Dekker; 2002. The myelodysplastic syndromes: pathobiology and clinical management.
-
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088. - PubMed
-
- Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their prevalence and costs. Jama. 1996;276:1473–1479. - PubMed
-
- Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–1587. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous